Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06782373 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
A Phase 2 study of VEXAS and Vexas Syndrome, sponsored by Swedish Orphan Biovitrum.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 20
- Study locations
NCT06782373: Recruiting Phase 2 study of VEXAS and Vexas Syndrome, sponsored by Swedish Orphan Biovitrum.
NCT06782373 is a Phase 2 study of VEXAS and Vexas Syndrome that is actively recruiting participants, run by Swedish Orphan Biovitrum. The registered enrollment target is 78 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06782373, a Phase 2 study of VEXAS and Vexas Syndrome, is actively recruiting participants, sponsored by Swedish Orphan Biovitrum.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 participants will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
Primary Outcome
Difference in the proportion of participants achieving OCR for the pairwise comparison of pacritinib dose A vs. placebo and pacritinib dose B plus placebo vs. placebo
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pacritinib
Study Locations (20)
Other
- Lille University Hospital Center - Lille
- Saint-Antoine Hospital - APHP - Paris
- Tenon Hospital - APHP - Paris
- Hospices Civils de Lyon - Lyon Sud - Pierre-Bénite
- University Hospital Center of Poitiers - Poitiers
- IUCT-Oncopole - Toulouse
Ohio
- Cleveland Clinic - Cleveland - Cleveland
- The James Cancer Hospital and Solove Research Institute - Columbus
Arizona
- Mayo Clinic - Scottsdale - Scottsdale
Maryland
- University of Maryland Medical Center Midtown Campus - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester - Rochester
New York
- NYU Langone Health - New York
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2028-05-22 |
| Phase | Phase 2 |
What NCT06782373 shows while recruiting
NCT06782373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 2 conditions, with VEXAS appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06782373 names 20 study sites across 14 states, led by Other, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT06782373 about?
NCT06782373 is a clinical study titled "A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)". This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 participants will be enrolled, randomized to either pacritinib dose A...
What is the current status of trial NCT06782373?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2025-05-28. Estimated completion is 2028-05-22.
What conditions does trial NCT06782373 study?
This clinical trial studies the following conditions: VEXAS, Vexas Syndrome.
What interventions are being tested in trial NCT06782373?
The interventions under investigation include: Placebo (DRUG), Pacritinib (DRUG).
Who is sponsoring clinical trial NCT06782373?
This trial is sponsored by Swedish Orphan Biovitrum, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06782373 being conducted?
This trial has 20 study locations across Arizona, Maryland, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for VEXAS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06782373's enrollment target sits among peer trials
78 884th of 2000 higher than 1,110 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI